Nucleoside analogue neuropathies

Mazen M Dimachkie MD

Peripheral Neuropathies

Updated 01.08.2024
Released 01.03.2000
Expires For CME 01.08.2027

Nucleoside analogue neuropathies

Author: Mazen M Dimachkie MD

See Contributor Disclosures

Editor: Louis H Weimer MD

Nucleoside analogue neuropathies

In This Article

Quick Link

Introduction

Historical note and terminology

Antiviral nucleoside analogues are a class of compounds that resemble natural nucleotide bases. When phosphorylated, they compete with endogenous nucleotides for binding to reverse transcriptase and cause termination of viral DNA chain elongation. Thus, they are potent inhibitors of the early phase of both HIV-1 and HIV-2 replication. Their individual use, or use in combination therapy, in patients with AIDS and AIDS-related complex has been associated with rapid suppression of serum p24 antigen levels, reduced infectious HIV titers in mononuclear cells, increases in CD4+ cell counts, and in some studies, improvement in the patient’s reported quality of life (87; 55; 58; 64; 31; 65; 43). In the past decade, multiple antiviral nucleoside analogues have been developed and tested in vivo and in vitro, including: zalcitabine (ddC), didanosine (ddI), stavudine (d4T), and lamivudine (3TC). Each of these compounds has been associated with a dose-dependent, distal sensory polyneuropathy, which often exacerbates the common disorders of peripheral nerves that are associated with HIV disease. For many patients, peripheral neuropathy is the dose-limiting side effect associated with antiviral nucleoside analogue therapy (59). Telbivudine (LdT) is a highly specific and potent synthetic thymidine nucleoside analogue. LdT inhibits hepatitis B virus (HBV) DNA polymerase, thereby interfering with hepatitis B viral replication. According to the package insert, peripheral neuropathy was reported as an adverse event in less than 1% of subjects receiving LdT monotherapy, whereas coadministration of LdT with pegylated interferon alfa-2a increases the risk and severity of peripheral neuropathy. More information can be accessed at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022011s013lbl.pdf. This hepatitis B drug was discontinued by Novartis in 2016. Tenofovir disoproxil fumarate is a nucleoside reverse transcriptase inhibitor with improved safety profile. At 24 weeks, 3% of cases developed neuropathy, and by week 48, only 5% had neuropathy (Tenofovir disoproxil fumarate fact sheet). A higher rate of peripheral neurotoxicity has been reported (61). Peak plasma concentration of antiviral nucleoside analogues generally occurs 1 to 2 hours following oral administration (62), with bioavailability in adults ranging from 40% to 88% (11; 85). Concentration in the CSF is approximately 20% of that in the plasma of adults, but the concentration is variable in children. Antiviral nucleoside analogues enter cells either with the aid of nucleoside carriers or by non-facilitated diffusion. The major route of excretion is renal, with approximately 70% of the compounds found unchanged in urine following intravenous dosing.

Therapeutic regimens for the treatment of HIV have stressed polypharmacy, combining various antiviral nucleoside analogues with each other and with protease inhibitors. Preliminary studies suggest that the pharmacokinetic properties of zalcitabine are not significantly altered by combination with other antiviral nucleoside analogues, as judged by peak serum concentrations, area under the plasma concentration-time curve, and serum half-life (54; 62). However, concentrations of didanosine have been reported to increase by 50% or more when coadministered with another antiviral nucleoside analogue (77). The pharmacodynamic, pharmacokinetic, and neurotoxic properties of antiviral nucleoside analogues used in combination with other putative therapies remain to be fully explored.

Clinical manifestations

Presentation and course

Antiviral nucleoside analogue therapy is generally associated with a painful, sensory, distal polyneuropathy, which is often the dose-limiting side effect (87; 56; 55; 13; 30; 74; 14; 51; 59; 43). This toxic neuropathy usually appears 2 to 3 months after initiation of treatment and may affect the hands early on. Progressive zalcitabine-induced neuropathy was confirmed in one patient by degenerative changes in a series of punch skin biopsies (52). There were no autonomic symptoms or evidence of cranial nerve dysfunction at any dose.

Sensory neuropathy characterized by pain and paresthesias has also been associated with didanosine (22; 63; 68; 03; 58; 43) and stavudine (15; 10; 60; 75).

Significant risk factors for the development of antiviral nucleoside analogue-induced peripheral neuropathy include age (72; 20), height (20), history of diabetes (14), nutritional deficiencies (59), previous exposure to antiviral nucleoside analogue compounds (47), co-treatment with interferon (31), acetylcarnitine deficiency (26), a history of heavy ethanol consumption (29), and a European mitochondrial haplogroup T (34). This group examined mtDNA single nucleotide polymorphisms (SNPs), called haplogroups, in 156 non-Hispanic black participants in the ACTG 384 study (Canter et 2010). These preliminary results suggest that belonging to mitochondrial subhaplogroup L1c (OR, 3.7 [95% CI, 1.1–12.0]; p=.03) is an independent predictor of peripheral neuropathy. This is in addition to multivariate analysis showing that randomization to ddI plus d4T and older age contribute to that risk.

In a prospective study, HIV-associated neuropathy, an elevated triglyceride level, and diabetes mellitus type 2 were each demonstrated to increase the risk of neuropathy (04). Surprisingly, the metabolic syndrome did not increase the risk of neuropathy. Specific aspects of the patient’s HIV status, including CD4+ cell counts, are also highly predictive of antiviral nucleoside analogue-induced neuropathies (59). Kelleher and colleagues report that there is a 17% increase in risk for every 100 cell/microL decrement in CD4+ cell counts (43).

The risk factors for peripheral neuropathy and symptomatic peripheral neuropathy were evaluated using longitudinal data from treatment-naive patients initiating combination antiretroviral therapy in 6 randomized AIDS Clinical Trials Group trials (24). In 573 patients who initiated neurotoxic therapy, peripheral neuropathy affected 27.4% and was significantly associated with older age and current protease inhibitor co-administration. Symptomatic neuropathy was less frequent (9.8%), with risk factors being older patient age, history of diabetes, protease inhibitor use, and, to a lesser extent, taller height. Older age also predicted lower odds of recovery after neurotoxic drug discontinuation. It is not clear if this protease effect is mediated by direct toxicity or indirectly through metabolic derangements such as insulin resistance.

There has been limited exposure of children to antiviral nucleoside analogue; however, studies to date indicate little evidence of induced peripheral neuropathy (46). In children, regimens containing zidovudine seem to be less neurotoxic than those containing d4T (79). One report of a 6-year-old girl with AIDS stated that didanosine was associated with the development of multiple, well-circumscribed retinal lesions characterized by hypertrophy or hypopigmentation of the retinal pigment epithelium (84).

Although the principal toxic insult associated with antiviral nucleoside analogues (other than AZT) has been peripheral neuropathy, muscle, pancreas, liver, and heart have also been affected (48). Pancreatitis has been especially associated with didanosine (38).

A study investigating the antiviral efficacy and safety of telbivudine (LdT) in combination with pegylated interferon (PegIFN) alpha-2a as compared to monotherapies in patients with chronic hepatitis B was prematurely terminated due to increased rates of peripheral neuropathy in the combination therapy group. Peripheral neuropathy occurred in 7 out of 50, 1 out of 54, and 0 out of 54 subjects assigned to combination therapy, LdT, and PegIFN groups, respectively. The onset of neuropathy in the combination group was 2 to 6 months after treatment onset and consisted mostly of peripheral neuropathy or sensory neuropathy, with recovery at last follow up in 50% and improvement in the other three cases following drug withdrawal. The seventh case on combination therapy experienced complete recovery from demyelinating neuropathy. The case of peripheral neuropathy in the LdT-only group had a delayed onset (14 months), compared well to the frequency of neuropathy from the full Novartis clinical study database (0.45%), and improved after stopping the drug (50). This hepatitis B drug was discontinued by Novartis in 2016.

In the interim World Health Organization guidelines of December 2018, the preferred and alternative first-line regimen for adults and adolescents included tenofovir disoproxil fumarate and 3TC combined with a third agent (World Health Organization 2018). In a study of Tenofovir-based combination antiretroviral therapy, 120 neuropathy-free and antiretroviral therapy–naive patients with HIV were followed up for 6 months (61). Nine percent of cases developed asymptomatic neuropathy, and 8% had symptomatic sensory neuropathy at 6 months. Forty percent of cases were detected within 50 days, and the remaining cases by 140 days. These researchers found active tuberculosis to be independently associated with the risk of developing sensory neuropathy.

Prognosis and complications

In most cases, the antiviral nucleoside analogue-induced neuropathy is reversible on discontinuation of treatment (02). Significant recovery occurred in 67% to 83% of subjects with clinically evident zalcitabine-induced neuropathy; however, there was often a period of “coasting” in which the neuropathy intensified immediately following cessation of treatment (13).

Clinical vignette

A 40-year-old male with HIV infection was treated with zalcitabine. At 7 weeks, he developed a sensory polyneuropathy. The predominant and presenting symptom was bilateral burning or shooting pain in the feet. This was soon followed by complaints of paresthesias, numbness, and weakness. Hyporeflexia of the Achilles reflex was an early and consistent neurologic sign of neuropathy, followed by clinically evident sensory loss, gait disturbances, and weakness. Elevation of vibration threshold in the great toe was the initial laboratory abnormality. At the time of maximal symptoms, mild to moderate nerve conduction abnormalities, suggestive of axonal dysfunction, were evident.

Biological basis

Etiology and pathogenesis

The common mechanism of antiviral nucleoside analogue toxicity appears to be interference with mtDNA and defective mitochondrial gene expression (18; 07; 48). These deficits lead to alterations in mitochondrial function and ultrastructure and ultimately to failure of cellular processes that depend heavily on high energy consumption. The specific subcellular target may be mtDNA gamma polymerase, which is essential for DNA homeostasis (80). Mitochondria in select elements of the peripheral nervous system, such as axons and Schwann cells, are especially sensitive to zalcitabine, didanosine, and stavudine, whereas mitochondria in skeletal muscle appear more easily affected by AZT. The reason for this differential susceptibility remains unclear. In a retrospective cohort study from the AIDS Clinical Trials Group, large mtDNA deletions and intraepidermal nerve fiber density (IENFD) were assessed in skin biopsies (66). Both IENFD and sural nerve action potential amplitude correlated with mitochondrial mutation burden in HIV-associated sensory neuropathy.

Several antiviral nucleoside analogue compounds, such as zalcitabine, have also been shown to inhibit the synthesis of select phospholipids (eg, phosphatidylcholine) in permeabilized rat hepatocytes (23). These effects would reasonably alter the phospholipid components of neuronal membranes, affecting their biophysical properties and possibly contributing to deficits in neuronal transduction and conduction associated with antiviral nucleoside analogue neurotoxicity. Investigation has focused on viral protein R (Vpr), a cytotoxic HIV-1 accessory protein synthesized late in the viral lifecycle (01). Vpr contributed to HIV neuropathy in cultured rat and human neurons and in a transgenic mouse model engineered to express Vpr in an immunosuppressed background. Vpr caused dorsal root ganglion neuronal damage, likely through cytosolic calcium activation and cytokine perturbation. Nerve growth factor (NGF) significantly protected mice sensory neurons from the effects of Vpr (82). Nerve growth factor acts through the tropomyosin-related kinase A receptor to block the Vpr-mediated decrease in axon outgrowth. Comparison of plasma miRNA profiles in HIV/AIDS patients with and without symptomatic distal symmetric polyneuropathy displayed ab increase in miR-455-3p (09). It turns out that miR-455-3p targets multiple genes implicated in peripheral nerve maintenance, including NGF and related genes. Based on neuronal cell culture data, the authors suggested that miR-455-3p may be a biomarker and may also have a pathogenic effect.

In vitro studies. Each of the antiviral nucleoside analogues evaluated have clear effects on mtDNA in tissue culture. Exposure of the neuronal cell line PC-12 to zalcitabine and didanosine results in a decrease in mtDNA, destruction of mitochondria, and an increase in lactate production (42). These effects can be partially rescued by the administration of uridine and pyruvate (41). Chronic treatment of dorsal root ganglion cultures to zalcitabine resulted in a reduction in mtDNA, which was associated with a decrease in the buffering of Ca2+ transient currents, which are partially mediated by mitochondria (83). Separate studies using a human lymphoblastoid cell line, CEM, have confirmed that zalcitabine is more potent than stavudine, which is in turn more potent than didanosine regarding the ability to alter mtDNA (19; 53). The ultrastructure of mitochondria was altered by each drug, including distortions and reductions in cristae and the presence of numerous vesicles. The induced changes appeared to display unique features for each compound evaluated (53). These differences may partially explain why various antiviral nucleoside analogues affect different targets (ie, Schwann cells, axon, muscle, pancreas) although each appears to principally alter mitochondrial function.

Animal studies. Marked morphologic and electrophysiologic changes were seen in New Zealand white rabbits treated with zalcitabine (50 to 250 mg/kg) for periods up to 18 weeks (06; 28). Myelin pathology consisted of severe myelin splitting, intramyelinic edema, myelin folding, and demyelination. Myelin changes were seen in the majority of large diameter fibers, and remyelination was prominent. Axonal changes were less evident and characterized by axonal loss and rare examples of shrunken axons or intralumenal phagocytes replacing axons within myelin sheaths. Pathology was present in both sensory and motor fibers, including cells in both the dorsal and ventral spinal roots. The changes were associated with profound reductions in both sensory and motor electrophysiologic measures (> 30% in velocity, > 70% in amplitude). No abnormalities of myelin, axons, or neurons were observed in sections of the cervical, thoracic, or lumbar spinal cord, brainstem at the level of the gracilis, retina, or brain (06).

In a subsequent study, mitochondrial changes were associated with 35 mg/kg of zalcitabine in the rabbit (27). Pathology consisted of the presence of cup-shaped mitochondria, which were arrayed in unusual patterns and complex aggregations. The earliest changes in mitochondria were seen at 16 weeks and were positively correlated with myelin pathology in individual animals. Neither didanosine nor stavudine were found to induce myelin, axonal or mitochondrial changes in rabbits, even at near lethal doses (eg, 1500 mg/kg) for periods of up to 24 weeks (81).

The behavioral, electrophysiologic and pathologic features of the zalcitabine-induced neuropathy in the rabbit appear to differ substantially from the clinical features of zalcitabine neuropathy in humans. The rabbit data suggest a myelinopathy of large diameter fibers, with only secondary axonal involvement. They also indicate a significant involvement of motor axons. In contrast, human exposure to zalcitabine is more consistent with a predominant small fiber, sensory, distal axonopathy. These differences may be related to the relatively high doses used in the rabbit study, to a possible unusual susceptibility of Schwann cell mitochondria in the rabbit, or to the interaction of HIV infection and zalcitabine toxicity in the human population studied.

Zalcitabine at doses of 3 to 10 mg/kg, produce electrophysiologic and axonal changes in Cynomolgus monkeys, with no evidence of demyelination (05). Initial changes consisted of a subtle slowing of maximal sensory nerve conduction velocity (approximately 10%) and an associated reduction in compound sensory amplitudes. No clear neuropathology was evident at the time of these early electrophysiologic changes. Following 38 weeks of treatment, axonal changes consisted of a statistically significant reduction in mean cross-sectional diameter of myelinated axons in the sural nerve and a reduction in the density of unmyelinated fibers. Didanosine has been reported to cause axonal neuropathy, electrophysiologic changes, and ultrastructural changes in axonal mitochondria in rats (67).

Epidemiology

In the early monotherapy studies, the neuropathy associated with zalcitabine was evident in all HIV-1-positive patients evaluated at the highest dose tested, ie, 0.06 mg/kg every 4 hours for a period of up to 12 weeks (13). Lower doses (0.03 to 0.005 mg/kg every 4 hours) were associated with a similar but less intense sensory neuropathy. The incidence of neuropathy was reduced to approximately 33% in subjects receiving 0.005 mg/kg every 4 hours (13) and 34% of subjects receiving 2.25 mg/day (14). Findings from the Delta trial suggest that peripheral neurotoxicity peaks at 90 days after the onset of nucleoside analogue treatment and that the risk is especially high in the zalcitabine/AZT combination recipients (08). Older age (35 to 44 years) and lower CD4 counts (< 150) were also associated with an increased risk of neuropathy.

As polypharmacy is increasingly used for the treatment of AIDS, interactions among synergistic or additive compounds and the use of alternating versus intermittent dosing regimens will take on added significance. For instance, a much lower incidence of neuropathy was seen when the same total dose of zalcitabine was given in a monthly alternating rather than weekly alternating fashion (76). Neuropathy was evident in only 2 of 56 patients receiving combinations of zidovudine and zalcitabine at doses that were clinically effective (54), and no serious neuropathy was evident in a second study, which included didanosine (36). In antiviral clinical trials using combination therapies, the prevalence of antiviral nucleoside analogue-induced peripheral neuropathy has been reduced to approximately 10% (72). The World Health Organization recommended that countries phase out the use of stavudine because of its long-term, irreversible side effects (86). In a study evaluating the evolution of symptomatic sensory neuropathy in 184 participants after initiation of antiretroviral therapy, pre-antiretroviral therapy 16% had neuropathy, and pain overall improved after 18 months of treatment (17). In those without baseline neuropathy, 18 per 100 person-years developed symptomatic neuropathy. It is noteworthy that 60% of cases receiving stavudine predicted reduced tendon reflexes but not incident symptomatic neuropathy cases. In another study from a tertiary referral hospital in southern Brazil, the prevalence of neuropathy (31.3%) was even more so increased in older patients and those with higher CD4 lymphocytes levels (12). This study was unique in that it also detected that smoking increased the odds ratio for neuropathy (3.4; p < 0.01).

In a report from South Africa, 72 of 75 self-identified Africans were started on tenofovir, emtricitabine, and efavirenz as first-line therapy (32). The researchers used the Brief Peripheral Neuropathy Screen amended by inclusion of pinprick sensitivity. Twelve percent were diagnosed with sensory neuropathy before starting treatment, and another 27% developed HIV-related sensory neuropathy in the following 6 to 8 months. The calcium/calmodulin kinase 2 (CaMKK2), which induces production of IL-1beta and TNF via the p38-MAPK pathway, is also expressed in the nervous system and plays a role in neuronal growth and repair. Three CAMKK2 haplotypes (2, 3, and 4) were associated with neuropathy after adjusting for body weight, nadir CD4 T-cell counts, and prior tuberculosis. In a time-to-neuropathy event modifier analysis of the multicenter ACTG study, 108 individuals initiating therapy had sufficient serum for analysis, including 30 neuropathy cases (39). Neuropathy onset was based on clinical symptoms or signs of neuropathy. These researchers’ preliminary results indicate that higher iron stores, the iron-loading hemochromatosis gene variant 187C>G, and lower levels for high-sensitivity C-reactive protein predicted delayed onset of neuropathy among self-reported white individuals.

In a systematic review and meta-analysis of HIV-related peripheral neuropathy, age and treatment with nucleoside analogue reverse transcriptase inhibitors are risk factors for developing HIV-related neuropathy (Julian at al 2021). The pooled prevalence of neuropathy in treatment-naive patients is 29% (95% CI: 9% to 62%), and it increased to 38% (29% to 48%) at later disease stages, with 53% (41% to 63%) being symptomatic. In addition to symptom management, discontinuation of drugs such as didanosine can improve or resolve symptoms. In a longitudinal study of adults living with HIV, peripheral neuropathy occurred in 21% of patients (78). Using machine learning algorithms, variables predictive of the development of neuropathy were HIV disease duration, peak plasma viral load, age, and low CD4+ T-cell count.

Management

Supportive measures and rehabilitation are discussed in another article: peripheral neuropathies.

The management of antiviral nucleoside analogue-induced neuropathies includes prompt cessation of therapy (when possible) or adjustment in the combination therapies utilized. Additional management tools include the treatment of pain with simple analgesia, augmented with antidepressants or anticonvulsive agents (59; 37). However, most of these drugs, with the exception of lamotrigine, have been demonstrated to be no more effective than placebo in relieving pain in HIV-related peripheral neuropathy (73).

It is important to treat HIV-related neuropathic pain, as it has a negative impact on health status and physical function (49). Furthermore, depression increases with increased pain severity, resulting in substantial clinical and economic burden. In this study of HIV-associated neuropathic pain, three quarters of patients had moderate to severe pain. Most patients were prescribed at least one medication for neuropathic pain, and these were most commonly narcotic analgesics or antiepileptic drugs and much less frequently a variety of antidepressant agents.

A double-blind placebo-controlled multicenter study of painful antiretroviral toxic neuropathy in patients with HIV-1 infection demonstrated efficacy in pain reduction of acetyl L-carnitine 500 mg administered 2 times per day intramuscularly (88). The oral study phase of acetyl L-carnitine 1000 mg 2 times per day did not show a statistically significant improvement. In a follow up report, Youle demonstrated an improvement in cutaneous nerve fiber density in acetyl L-carnitine recipients, which was maintained over a 4-year period of treatment (88).

In a placebo-controlled 12-week study of painful HIV neuropathy, 33% of subjects placed on high-concentration capsaicin dermal patches (NGX-4010) experienced significant pain relief, whereas only 18% of controls had this effect (70). In another study, the mean percent change from baseline in Numeric Pain Rating Scale (NPRS) score to weeks 2 to 12 was not statistically significant between active drug and placebo, but trends toward pain improvement were detected after a single 30-minute NGX-4010 treatment (21). Out of the 307 patients completing the former 12-week, randomized, double-blind phase of the study, 272 entered a 40-week, open-label phase and received up to three 60-minute NGX-4010 treatments (71). Patients recorded their average pain for the past 24 hours each day using the NPRS. The percentage NPRS score reduction from baseline to weeks 2 to 12 after treatment ranged from 23% to 26%. Patient Global Impression of Change and Clinician Global Impression of Change questionnaires also demonstrated benefits and adverse events were mild to moderate and cutaneous. In a meta-analysis of randomized and controlled studies of 8% capsaicin patch, baseline pain intensity score of less than or equal to 4 and female gender were predictors of sustained and complete response (40).

References

01: Acharjee S, Noorbakhsh F, Stemkowski PL, et al. HIV-1 viral protein R causes peripheral nervous system injury associated with in vivo neuropathic pain. FASEB J 2010;24(11):4343-53. PMID 20628092
02: Adkins JC, Peters DH, Faulds D. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection. Drugs 1997;53:1054-80. PMID 9179531
03: Allan JD, Connolly KJ, Fitch H, et al. Long-term follow-up of didanosine administered orally twice daily to patients with advanced human immunodeficiency virus infection and hematologic intolerance of zidovudine. Clin Infect Dis 1993;16:S46-51. PMID 8425019
04: Ances BM, Vaida F, Rosario D, et al; CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Metabolic Study Group. Role of metabolic syndrome components in HIV-associated sensory neuropathy. AIDS 2009;23(17):2317-22. PMID 19823068
05: Anderson T, Davidovich A, Arezzo J, Brosnan C. Comparative neurotoxicity of dideoxycytidine in monkeys and rabbits. Toxicol Lett Suppl 1992b:191. PMID 7515130
06: Anderson TD, Davidovich A, Arceo R, Brosnan C, Arezzo J, Schaumburg H. Peripheral neuropathy induced by 2’, 3’-dideoxycytidine: a rabbit model of 2’, 3’-dideoxycytidine neurotoxicity. Lab Invest 1992a;66:63-74. PMID 1309930
07: Anderson TD, Davidovich A, Feldman D, et al. Mitochondrial schwannopathy and peripheral myelinopathy in a rabbit model of dideoxycytidine neurotoxicity. Lab Invest 1994;70:724-39. PMID 7515130
08: Arenas-Pinto A, Bhaskaran K, Dunn D, Weller IV. The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial. Antivir Ther 2008;13(2):289-95. PMID 18505180
09: Asahchop EL, Branton WG, Krishnan A, et al. HIV-associated sensory polyneuropathy and neuronal injury are associated with miRNA-455-3p induction. JCI Insight 2018;3(23). PMID 30518697
10: Bacellar H, Munoz A, Miller EN, et al. Temporal trends in the incidence of HIV-1-related neurologic diseases: multicenter AIDS cohort study, 1985-1992. Neurology 1994;44:1892-900. PMID 7936243
11: Balis FM, Pizzo PA, Butler KM, et al. Clinical pharmacology of 2’, 3’-dideoxyinosine in human immunodeficiency virus-infected children. J Infect Dis 1992;165:99-104. PMID 1727902
12: Benevides MLACSE, Filho SB, Debona R, Bergamaschi ENC, Nunes JC. Prevalence of peripheral neuropathy and associated factors in HIV-infected patients. J Neurol Sci 2017;375:316-20. PMID 28320159
13: Berger AR, Arezzo JC, Schaumburg HH, et al. 2’, 3’-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology 1993;43:358-62. PMID 8382349
14: Blum AS, Dal Pan GJ, Feinberg J, et al. Low-dose zalcitabine-related toxic neuropathy: frequency, natural history, and risk factors. Neurology 1996;46(4):999-1003. PMID 8780079
15: Browne MJ, Mayer KH, Chafee SB, et al. 2’, 3’-didehydro-3’-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: a phase I trial. J Infect Dis 1993;167:21-9. PMID 8093363
16: Canter JA, Robbins GK, Selph D, et al; AIDS Clinical Trials Group Study 384 Team; New Work Concept Sheet 273 Team. African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy. J Infect Dis 2010;201(11):1703-7. PMID 20402593
17: Centner CM, Little F, Van Der Watt JJ, et al. Evolution of sensory neuropathy after initiation of antiretroviral therapy. Muscle Nerve 2018;57(3):371-9. PMID 28561925
18: Chen CH, Cheng YC. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2’, 3’-deoxythymidine. J Biol Chem 1989;264:11934-7. PMID 2745424
19: Chen CH, Vazquez-Padua M, Cheng YC. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 1991;39:625-8. PMID 1851960
20: Cherry CL, Affandi JS, Imran D, et al. Age and height predict neuropathy risk in patients with HIV prescribed stavudine. Neurology 2009;73(4):315-20. PMID 19636052
21: Clifford DB, Simpson DM, Brown S, et al. A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J Acquir Immune Defic Syndr 2012;59(2):126-33. PMID 22067661
22: Connolly KJ, Allan JD, Fitch H, et al. Phase I study of 2’, 3’-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine. Am J Med 1991;91:471-8. PMID 1659189
23: De Groote K, Naesens L, Balzarini J, Baes MI, Declercq PE. Effects of 2', 3'-dideoxycytidine and 2',3'-dideoxycytidine 5'-triphosphate on phospholipid metabolism in permeabilized rat hepatocytes. Biochem Pharmacol 1997;54:713-9. PMID 9310348
24: Evans SR, Ellis RJ, Chen H, et al. Peripheral neuropathy in HIV: prevalence and risk factors. AIDS 2011;25(7):919-28. PMID 21330902
25: Evans SR, Lee AJ, Ellis RJ, Chen H, Wu K, Bosch RJ, Clifford DB. HIV peripheral neuropathy progression: protection with glucose-lowering drugs. J Neurovirol 2012;18(5):428-33. PMID 22806348
26: Famularo G, Moretti S, Marcellini S, et al. Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. AIDS 1997;11:185-90. PMID 9030365
27: Feldman D, Anderson TD. Schwann cell mitochondrial alterations in peripheral nerves of rabbits treated with 2’, 3’-dideoxycytidine. Acta Neuropathol (Berl) 1994;1:71-80. PMID 8140896
28: Feldman D, Brosnan C, Anderson T. Ultrastructure of peripheral neuropathy induced in rabbits by 2’, 3’-dideoxycytidine. Lab Invest 1992;66:75-85. PMID 1309931
29: Fichtenbaum CJ, Clifford DB, Powderly WG. Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:169-74. PMID 7552481
30: Fischl MA, Olson RM, Follansbee SE, et al. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann Intern Med 1993;118:762-9. PMID 8097082
31: Fischl MA, Richman DD, Saag M, et al. Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. AIDS Clinical Trials Group Study 197. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:247-53. PMID 9402071
32: Gaff J, Pillay P, Cherry C, Laws SM, Price P, Kamerman P. The role of CAMKK2 polymorphisms in HIV-associated sensory neuropathy in South Africans. J Neurol Sci 2020;416:116987. PMID 32585444
33: Herrmann DN, McDermott MP, Sowden JE, et al. Is skin biopsy a predictor of transition to symptomatic HIV neuropathy. A longitudinal study. Neurology 2006;66:857-61. PMID 16567702
34: Hulgan T, Haas DW, Haines JL, et al. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trial group study. AIDS 2005;19(13):1341-9. PMID 16103764
35: Hung CF, Gibson SA, Letendre SL, et al. Impact of long-term treatment with neurotoxic dideoxynucleoside antiretrovirals: implications for clinical care in resource-limited settings. HIV Med 2008;9(9):731-7. PMID 18651859
36: Jablonowski H. Studies of zidovudine in combination with didanosine zalcitabine. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:S52-6. PMID 8595509
37: Julian T, Rekatsina M, Shafique F, Zis P. Human immunodeficiency virus-related peripheral neuropathy: a systematic review and meta-analysis. Eur J Neurol 2021;28(4):1420-31. PMID 33226721
38: Kahn J. New developments in the clinical use of didanosine. J Acquir Immune Defic Syndr 1993;6:S47-50. PMID 8426301
39: Kallianpur AR, Wen W, Erwin AL, Clifford DB, Hulgan T, Robbins GK. Higher iron stores and the HFE 187C>G variant delay onset of peripheral neuropathy during combination antiretroviral therapy. PLoS One 2020;15(10):e0239758. PMID 33057367
40: Katz NP, Mou J, Paillard FC, Turnbull B, Trudeau J, Stoker M. Predictors of response in patients with postherpetic neuralgia and HIV-associated neuropathy treated with the 8% capsaicin patch (Qutenza). Clin J Pain 2015;31(10):859-66. PMID 25503598
41: Keilbaugh SA, Hobbs GA, Simpson MV. Anti-human immunodeficiency virus type 1 therapy and peripheral neuropathy: prevention of 2’, 3’-dideoxycytidine toxicity in PC 12 cells, a neuronal model, by uridine and pyruvate. Mol Pharmacol 1993;44:702-6. PMID 8232219
42: Keilbaugh SA, Prusoff WH, Simpson MV. The PC-12 cell as a model for studies of mechanism of induction of peripheral neuropathy by anti-HIV 1 dideoxynucleoside analogs. Biochem Pharmacol 1991;42:R5-8. PMID 1648918
43: Kelleher T, Cross A, Dunkle L. Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine. Clin Ther 1999;21:1182-92. PMID 10463516
44: Keswani SC, Chander B, Hasan C, et al. FK506 is neuroprotective in a model of antiretroviral toxic neuropathy. Ann Neurol 2003;53(1):57-64. PMID 12509848
45: Keswani SC, Leitz GJ, Hoke A. Erythropoietin is neuroprotective in models of HIV sensory neuropathy. Neurosci Lett 2004;371(2-3):102-5. PMID 15519737
46: Kline MW, Fletcher CV, Federici ME, et al. Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects. Pediatrics 1996;97:886-90. PMID 8657531
47: LeLacheur SF, Simon GL. Exacerbation of dideoxycytidine-induced neuropathy with dideoxyinosine. J Acquir Immune Defic Syndr 1991;4:538-9. PMID 1849990
48: Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995;1:417-22. PMID 7585087
49: Mann R, Sadosky A, Schaefer C, et al. Burden of HIV-related neuropathic pain in the United States. J Int Assoc Provid AIDS Care 2016;15(2):114-25. PMID 26173942
50: Marcellin P, Wursthorn K, Wedemeyer H, et al. Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. J Hepatol 2015;62(1):41-7. PMID 25152207
51: Markus R, Brew BJ. HIV-1 peripheral neuropathy and combination antiretroviral therapy. Lancet 1998;352:1906-7. PMID 9863794
52: McCarthy BG, Hsieh ST, Stocks A, et al. Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology 1995;45:1848-55. PMID 7477980
53: Medina DJ, Tsai CH, Hsiung GD, Cheng YC. Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides. Antimicrob Agents Chemother 1994;38:1824-8. PMID 7986014
54: Meng TC, Fischl MA, Boota AM, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study. Ann Intern Med 1992;116:13-20. PMID 1345755
55: Merigan TC, Skowron G. Safety and tolerance of dideoxycytidine as a single agent. Results of early-phase studies in patients with acquired immunodeficiency syndrome AIDS) or advanced AIDS-related complex. Am J Med 1990;88:11S-15S. PMID 23019803
56: Merigan TC, Skowron G, Bozzette SA, et al. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections: a phase I and II study. Ann Intern Med 1989;110:189-94. PMID 2536257
57: Miller RG. Neuromuscular complications of human immunodeficiency virus infection and antiretroviral therapy. West J Med 1994;160:447-52. PMID 8048229
58: Moyle GJ, Nelson MR, Hawkins D, Gazzard BG. The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine. Q J Med 1993;86:155-63. PMID 8387218
59: Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretroviral: risk factors, incidence and management. Drug Saf 1998;19:481. PMID 9880091
60: Petersen EA, Ramirez-Ronda CH, Hardy WD, et al. Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J Infect Dis 1995;171:S131-9. PMID 7861018
61: Pillay P, Wadley AL, Cherry CL, Karstaedt AS, Kamerman PR. Clinical diagnosis of sensory neuropathy in HIV patients treated with tenofovir: A 6-month follow-up study. J Peripher Nerv Syst 2019;24(4):304-13. PMID 31587421
62: Rana KZ, Dudley MN. Clinical pharmacokinetics of stavudine. Clin Pharmacokinet 1997;33:276-84. PMID 9342503
63: Rathbun RC, Martin ES. Didanosine therapy in patients intolerant of or failing zidovudine therapy. Ann Pharmocother 1992;26:1347-51. PMID 1362093
64: Riddler SA, Anderson RE, Mellors JW. Antiviral activity of stavudine. Antiviral Res 1995;27:189-203. PMID 8540743
65: Rouleau D, Conway B, Raboud J, et al. Stavudine plus lamivudine in advanced human immunodeficiency virus disease: a short-term pilot study. J Infectious Dis 1997;176:1156-60. PMID 9359713
66: Roda RH, Bargiela D, Chen W, et al. Large mitochondrial DNA deletions in HIV sensory neuropathy. Neurology 2021;97(2):e156-65. PMID 33947785
67: Russel JW, Cupler EJ, Dalakas MC. Electrophysiological and pathological changes in 2’, 3’-dideoxycytidine (ddC)-induced neuropathy in an animal model. Ann Neurol 1995;38:306.
68: Shelton MJ, O’Donnell AM, Morse GD. Didanosine. Ann Pharmacother 1992;26:660-70. PMID 1350471
69: Shikuma CM, Bennett K, Ananworanich J, et al. Distal leg epidermal nerve fiber density as a surrogate marker of HIV-associated sensory neuropathy risk: risk factors and change following initial antiretroviral therapy. J Neurovirol 2015;21(5):525-34. PMID 26002840
70: Simpson DM, Brown S, Tobias J; NGX-4010 C107 Study Group. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 2008;70(24):2305-13. PMID 18541884
71: Simpson DM, Brown S, Tobias JK, Vanhove GF, NGX-4010 C107 Study Group. NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: results of a 52-week open-label study. Clin J Pain 2014;30(2):134-42. PMID 23446088
72: Simpson DM, Katzenstein DA, Hughes MD, et al. Neuromuscular function in HIV infection: analysis of a placebo-controlled combination antiretroviral trial. AIDS Clinical Group 175/801 Study Team. AIDS 1998;12:2425-32. PMID 9875580
73: Simpson DM, McArthur JC, Olney R, et al. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology 2003;60(9):1508-14. PMID 12743240
74: Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:153-61. PMID 7749792
75: Skowron G. Biologic effects and safety of stavudine: an overview of phase I and II clinical trials. J Infect Dis 1995;171:S113-7. PMID 7861015
76: Skowron G, Bozzette SA, Lim L, et al. Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Ann Intern Med 1993;118:321-30. PMID 8094279
77: Taburet AM, Singlas E. Drug interactions with antiviral drugs. Clin Pharmacokinetics 1996;30:385-401. PMID 8743337
78: Tu W, Johnson E, Fujiwara E, Gill MJ, Kong L, Power C. Predictive variables for peripheral neuropathy in treated HIV type 1 infection revealed by machine learning. AIDS 2021;35(11):1785-93. PMID 34033588
79: Van Dyke RB, Wang L, Williams PL; Pediatric AIDS Clinical Trials Group 219C Team. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. J Infect Dis 2008;198(11):1599-608. PMID 19000014
80: Wallace DC. Diseases of the mitochondrial DNA. Annu Rev Biochem 1992;61:1175-212. PMID 1497308
81: Warner WA, Bregman CL, Comereski CR, et al. Didanosine (ddI) and stavudine (d4T): absence of peripheral neurotoxicity in rabbits. Food Chem Toxicol 1995;33:1047-50. PMID 8847000
82: Webber CA, Salame J, Luu GL, et al. Nerve growth factor acts through the TrkA receptor to protect sensory neurons from the damaging effects of the HIV-1 viral protein, Vpr. Neuroscience 2013;252:512-25. PMID 23912036
83: Werth JL, Zhou B, Nutter LM, Thayer SA. 2’, 3’-dideoxycytidine alters calcium buffering in cultured dorsal root ganglion neurons. Mol Pharmacol 1994;45:1119-24. PMID 8022405
84: Whitcup SM, Dastgheib K, Nussenblatt RB, et al. A clinicopathologic report of the retinal lesions associated with didanosine. Arch Ophthalmol 1994;112:1594-8. PMID 7993216
85: Whittington R, Brogden RN. Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS). Drugs 1992;44:656-83. PMID 1281077
86: World Health Organization. New HIV recommendations to improve health, reduce infections and save lives. News Release. 2009.
87: Yarchoan R, Perno CF, Thomas RV, et al. Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet 1988;1(8577):76-81. PMID 2891981
88: Youle M. Acetyl-L-carnitine in HIV-associated antiretroviral toxic neuropathy. CNS Drugs 2007;21 Suppl 1:25-30. PMID 17696590
89: Youle M, Osio M; ALCAR Study Group. A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Med 2007;8(4):241-50. PMID 17461852

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Mazen M Dimachkie MD

Dr. Dimachkie, Director of the Neuromuscular Disease Division and Executive Vice Chairman for Research Programs, Department of Neurology, The University of Kansas Medical Center received consultant honorariums from Abata/Third Rock, Abcuro, Amicus, ArgenX, Astellas, Cabaletta Bio, Catalyst, CNSA, Covance/LabCorp, CSL Behring, Dianthus, EMD Serono/Merck, Horizon, Ig Society Inc, Ipsen, Janssen, Octapharma, Priovant, Ra Pharma/UCB Biopharma, Sanofi Genzyme, Shire/Takeda, Treat NMD/TACT, and Valenza Bio. Dr. Dimachikie also received research grants from Alexion/Astra Zaneca, Amicus, Astellas, Catalyst, CSL Behring, EMD Serono/Merck, Genentech, Grifols, GSK, Horizon, Janssen, Mitsubishi Tanabe Pharma, MT Pharma, Novartis, Octapharma, Priovant, Ra Pharma/UCB Biopharma, Sanofi Genzyme, Sarepta Therapeutics, Shire/Takeda, and TMA.
See Profile

Editor

Louis H Weimer MD

Dr. Weimer of Columbia University has no relevant financial relationships to disclose.
See Profile

Former Authors

Joseph C Arezzo PhD (original author) and Kamlesh Patel MD

Patient Profile

Age range of presentation: 0 month to 65+ years
Sex preponderance: male=female
Heredity: none
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Nucleoside analogue neuropathies

Associated Disorders

Distal-sensory polyneuropathy
Peripheral neuropathy

Differential Diagnosis

AIDS
HIV
antiviral nucleoside analogue-induced neuropathy

Also Relevant

Acquired cytomegalovirus
AIDS and HIV: neurologic manifestations and complications
Clinical evaluation of peripheral neuropathies
Congenital HIV-1 infection
Peripheral nerve complications of HIV-1 infection

Clinical Categories

Peripheral Neuropathies

Nucleoside analogue neuropathies

Nucleoside analogue neuropathies

Introduction

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Associated or underlying disorders

Diagnostic workup

Management

References

Contributors

Author

Editor

Former Authors

Patient Profile

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Leukodystrophies

Neurolymphomatosis

Spinal accessory neuropathy

Thallium neuropathy

Bell palsy

Acute autonomic neuropathies

Tibial nerve injuries

Acute inflammatory demyelinating polyradiculoneuropathy

Nucleoside analogue neuropathies

Introduction

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Associated or underlying disorders

Diagnostic workup

Management

References

Contributors

Author

Editor

Former Authors

Patient Profile

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Leukodystrophies

Neurolymphomatosis

Spinal accessory neuropathy

Thallium neuropathy

Bell palsy

Acute autonomic neuropathies

Tibial nerve injuries

Acute inflammatory demyelinating polyradiculoneuropathy

This is an article preview.
Start a Free Account
to access the full version.